GoAI
Get started
CapsoVision, Inc. logo

CapsoVision, Inc.

CV

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$6.02

+$0.11 · +1.86%

Aug 21, 4:00 PM ET

CV company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Kang-Huai Wang
Listed since
Jul 2, 2025
Employees
99

Market position

Day range

Current $6.02

52-week range

Current $6.02

Open
$5.95
Previous close
$5.91
Volume
68.65K
0.5× average
Average volume
138.61K
Average daily volume
Market cap
300.78M USD
Beta
-2.37
Market reference 1
50-day average
$6.668
-9.72% below average
200-day average
$6.7485
-10.80% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-7.52×
P/B (TTM)
22.83×
P/S (TTM)
21.65×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
50.88%
Operating margin
-158.64%
Net margin
-214.74%

Financial health

Debt / equity
0.05×
Altman Z-score
16.79
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%-17%-115%-213%Gross margin, FY2023: 56.30%Gross margin, FY2024: 54.24%Gross margin, FY2025: 52.92%Operating margin, FY2023: -116.34%Operating margin, FY2024: -169.42%Operating margin, FY2025: -188.25%Net margin, FY2023: -115.91%Net margin, FY2024: -169.26%Net margin, FY2025: -186.77%FY2023FY2024FY2025
Gross margin FY2023 56.30%. Gross margin FY2024 54.24%. Gross margin FY2025 52.92%. Operating margin FY2023 -116.34%. Operating margin FY2024 -169.42%. Operating margin FY2025 -188.25%. Net margin FY2023 -115.91%. Net margin FY2024 -169.26%. Net margin FY2025 -186.77%.

Income trends

Revenue

13.55M USD+15.29%

Operating income

−25.52M USD-28.11%

Net income

−25.32M USD-27.22%
Income trends across reported periods17.46M USD1.83M USD−13.8M USD−29.42M USDRevenue, FY2023: 9.75M USDRevenue, FY2024: 11.76M USDRevenue, FY2025: 13.55M USDOperating income, FY2023: −11.35M USDOperating income, FY2024: −19.92M USDOperating income, FY2025: −25.52M USDNet income, FY2023: −11.31M USDNet income, FY2024: −19.9M USDNet income, FY2025: −25.32M USDFY2023FY2024FY2025
Revenue FY2023 9.75M USD. Revenue FY2024 11.76M USD. Revenue FY2025 13.55M USD. Operating income FY2023 −11.35M USD. Operating income FY2024 −19.92M USD. Operating income FY2025 −25.52M USD. Net income FY2023 −11.31M USD. Net income FY2024 −19.9M USD. Net income FY2025 −25.32M USD.
Metric (USD)FY2025FY2024FY2023
Revenue13.55M USD11.76M USD9.75M USD
Cost of goods sold6.38M USD5.38M USD4.26M USD
Gross profit7.17M USD6.38M USD5.49M USD
Research and development18.31M USD15.12M USD9.33M USD
Selling, general, and administrative14.38M USD11.17M USD7.51M USD
Operating expenses32.69M USD26.29M USD16.84M USD
Interest income269K USD26K USD49K USD
Depreciation and amortization567K USD521K USD388K USD
Operating income−25.52M USD−19.92M USD−11.35M USD
Net income−25.32M USD−19.9M USD−11.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
17%
1 beat, 5 misses, 0 met estimates
Average EPS surprise
-478.93%
6 comparable reports
Latest EPS result
-0.15
Estimate -0.13 · Miss by 15.38%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.79-1.48-2.17Q2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported May 9, 2025: actual -1.31, estimate -0.11, surprise -1090.91%, Miss. Q3 2025, reported Aug 14, 2025: actual -2.02, estimate -0.11, surprise -1736.36%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.17, estimate -0.14, surprise -21.43%, Miss. Q1 2026, reported Mar 26, 2026: actual -0.16, estimate -0.17, surprise +5.88%, Beat. Q2 2026, reported May 14, 2026: actual -0.15, estimate -0.13, surprise -15.38%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.15, estimate -0.13, surprise -15.38%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.14, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.47M3.86M3.24M2.62MQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported May 9, 2025: actual 2.79M USD, estimate 3.25M USD, surprise -14.02%, Miss. Q3 2025, reported Aug 14, 2025: actual 3.32M USD, estimate 3.25M USD, surprise +2.11%, Beat. Q4 2025, reported Nov 13, 2025: actual 3.54M USD, estimate 4.3M USD, surprise -17.74%, Miss. Q1 2026, reported Mar 26, 2026: actual 3.9M USD, estimate 4.15M USD, surprise -6.05%, Miss. Q2 2026, reported May 14, 2026: actual 2.79M USD, estimate 2.98M USD, surprise -6.18%, Miss. Q3 2026, reported Aug 13, 2026: actual 3.64M USD, estimate 3.81M USD, surprise -4.46%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 3.72M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

CV news

seekingalpha.com

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

CapsoVision Q2 Earnings Call Highlights

CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development…

Read source
globenewswire.com

CapsoVision Reports Second Quarter 2026 Financial Results

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported…

Read source
globenewswire.com

CapsoVision® Announces International Launch of AI Highlights

SARATOGA, Calif. , Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced…

Read source
globenewswire.com

CapsoVision® Announces International Launch of AI Highlights

AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review of small bowel…

Read source
globenewswire.com

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced…

Read source

CV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.09M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.92M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.94M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.29M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
714.13K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
664.47K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
244.9K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
99.76K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%

Continue in GoAI

Research CV

research.disclaimer